Ovarian Cancer Market: Epidemiology, Treatments, and Key Players - DelveInsight | Leading companies active in this space include pharmaand GmbH, GlaxoSmithKline, AbbVie, Eli Lilly, Novartis, Roche, Ve

The High-Grade vs. Low-Grade Serous Ovarian Cancer market size in the 7MM is expected to grow from USD 3,012 million in 2025 to USD 5,703 million in 2034.

Emerging therapies for ovarian cancer, including Tisotumab Vedotin, Pembrolizumab, Adavosertib, AVB-500, and others, are expected to drive significant growth in the ovarian cancer market in the coming years.

DelveInsight has released a new report titled "Ovarian Cancer - Market Insights, Epidemiology, and Market Forecast-2034," providing a comprehensive analysis of ovarian cancer, covering historical and projected epidemiology as well as market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Discover about the Ovarian cancer market report @ https://www.delveinsight.com/report-store/ovarian-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Ovarian cancer Market Report:

*
In 2024, the ovarian cancer market across the 7 major markets (7MM) was valued at approximately USD 2.7 billion, with growth expected to be driven by the launch of novel therapies. Early detection remains challenging due to the absence of a universally accepted screening method, and symptoms often go unnoticed until the disease has advanced.

*
The United States reported the highest number of new cases of high- and low-grade serous ovarian cancer (HGSOC and LGSOC) in 2024, totaling roughly 37,600 cases. Within the EU4 and the UK, the UK had the largest number of LGSOC cases, followed by Germany, with Spain reporting the fewest.

*
For over three decades, platinum-based chemotherapy has been the mainstay of ovarian cancer treatment. While initially effective, many patients eventually develop resistance upon recurrence. In maintenance therapy, PARP inhibitors dominate the market, including ZEJULA (niraparib), LYNPARZA (olaparib), and RUBRACA (rucaparib), all FDA-approved. LYNPARZA currently leads the market, followed by ZEJULA. However, recent restrictions on PARP inhibitors reflect evolving treatment strategies, particularly concerning their long-term survival benefits, and are now primarily recommended for patients with BRCA mutations.

*
In 2024, the U.S. held the largest ovarian cancer market share within the 7MM, valued at approximately USD 1,922 million. Among the EU4 and the UK, Germany led the market, while Spain accounted for the smallest share. The treatment landscape for LGSOC remains significantly underserved, with TAFINLAR + MEKINIST as the only FDA-approved therapy. Approval of Avutometinib + Defactinib is anticipated in 2025. The first-line (1L) treatment market for HGSOC was valued at nearly USD 1,088 million in 2024, while the 1L LGSOC market reached approximately USD 3.2 million.

*
In the LGSOC segment, TAFINLAR + MEKINIST currently dominates, with market expansion expected following the 2025 anticipated approval of Avutometinib + Defactinib. ELAHERE, an antibody-drug conjugate (ADC) targeting FR-positive platinum-resistant ovarian cancer, has also gained traction, achieving U.S. sales exceeding USD 470 million in 2024 and accelerating global commercialization efforts.

*
For HGSOC, promising first-line combination therapies in development include JEMPERLI + niraparib + chemotherapy and KEYTRUDA + chemotherapy followed by LYNPARZA maintenance. Additional pipeline therapies-such as Avutometinib + Defactinib, Relacorilant, Oregovomab, Luveltamab Tazevibulin, and Raludotatug deruxtecan-are expected to broaden treatment options and drive market growth, particularly as cases of both high- and low-grade serous ovarian cancer rise.

*
In February 2025, the FDA granted Fast Track designation to CUSP06, an ADC targeting CDH6, for treating patients with platinum-resistant ovarian cancer.

*
Key companies active in the ovarian cancer space include pharmaand GmbH, GlaxoSmithKline, AbbVie, Eli Lilly, Novartis, Roche, Verastem Oncology, Corcept Therapeutics, AstraZeneca, Genmab, Genelux Corporation, Mural Oncology, Daiichi Sankyo, Merck, Sutro Biopharma, Bristol-Myers Squibb, and others, all pursuing novel therapies to enhance the treatment landscape.

*
Promising emerging ovarian cancer therapies include Tisotumab Vedotin, Pembrolizumab, Adavosertib, AVB-500, and other investigational agents.

Ovarian cancer Overview

Ovarian cancer treatment typically involves a combination of surgery, chemotherapy, and targeted therapies. Surgery aims to remove cancerous tissue, while chemotherapy-administered orally or intravenously-works to destroy remaining cancer cells. Targeted therapies are designed to inhibit cancer growth and are selected based on specific diagnostic test results. For high-grade serous ovarian cancer (HGSOC), the most common subtype, standard care generally includes surgery plus chemotherapy. Early-stage patients usually undergo surgery followed by approximately six cycles of chemotherapy, whereas advanced-stage patients may first receive chemotherapy to shrink tumors, followed by surgery and additional chemotherapy. While a patient's BRCA or HRD mutation status does not influence initial treatment, it plays a key role in guiding maintenance therapy, particularly the use of PARP inhibitors to reduce recurrence risk. Research continues into novel approaches, including immunotherapies, cancer vaccines, and intraperitoneal radiation.

Despite these advancements, disparities in care persist, particularly among racial minorities and low-income populations. Barriers such as limited access to specialized care, geographic and financial constraints, and lack of awareness about available treatments often result in delays, poorer outcomes, and underutilization of effective therapies. Early detection is further challenged by the absence of routine screening and limited BRCA testing awareness in underserved communities. Addressing these gaps will require improved access to care, enhanced education, and expanded early detection initiatives.

Read more about ovarian cancer, diagnosis, treatment options @ https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Ovarian cancer Market Outlook

Ovarian cancer treatment has evolved over time, generally combining therapies such as immunosuppressive agents-including corticosteroids, DMARDs, and biologics-with physical therapy and supportive care. Despite these advancements, there remains a need for more effective, targeted treatments with improved safety profiles. Emerging options, including biologics and small-molecule inhibitors, show promise in enhancing patient outcomes and influencing future market dynamics.

Intravenous immunoglobulin (IVIg) has demonstrated efficacy as a first-line monotherapy in approximately 50% of patients with idiopathic inflammatory myopathies, often producing a response within three weeks in responders. For patients who do not respond to standard therapies like corticosteroids, immunosuppressants, or IVIg, intravenous cyclophosphamide may be considered as a fourth-line treatment, though its use is limited due to significant risks and is reserved for severe, treatment-resistant cases. Overall, treatment strategies are personalized, taking into account disease severity, response to prior therapies, and clinical judgment.

Discover how the Ovarian cancer market is rising in the coming years @ https://www.delveinsight.com/report-store/ovarian-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Ovarian cancer Emerging Drugs

*
Avutometinib (VS-6766) + Defactinib (VS-6063): Verastem Oncology

*
Raludotatug deruxtecan: Daiichi Sankyo

Ovarian cancer Emerging Drugs

*
RUBRACA (rucaparib): pharma& GmbH

*
ZEJULA (niraparib): GlaxoSmithKline

Scope of the Ovarian cancer Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Ovarian cancer Companies: pharmaand GmbH, GlaxoSmithKline, Abbvie, Eli Lilly, Novartis, Roche, Verastem Oncology, Corcept Therapeutics, AstraZeneca, Genmab, Genelux Corporation, Mural Oncology, Daiichi Sankyo, Merck, Sutro Biopharma, Bristol-Myers Squibb, and others

*
Key Ovarian cancer Therapies: Tisotumab Vedotin, Pembrolizumab, Adavosertib, AVB-500, and others

*
Ovarian cancer Therapeutic Assessment: Ovarian cancer current marketed and Ovarian cancer emerging therapies

*
Ovarian cancer Market Dynamics: Ovarian cancer market drivers and Ovarian cancer market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Ovarian cancer Unmet Needs, KOL's views, Analyst's views, Ovarian cancer Market Access and Reimbursement

To know what's more in our Ovarian cancer report, visit https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key benefits of the Ovarian cancer Market Report:

*
Ovarian cancer market report covers a descriptive overview and comprehensive insight of the Ovarian cancer Epidemiology and Ovarian cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

*
The Ovarian cancer market report provides insights into the current and emerging therapies.

*
The Ovarian cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The Ovarian cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Ovarian cancer market.

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Ovarian cancer Patient Share (%) Overview at a Glance

5. Ovarian cancer Market Overview at a Glance

6. Ovarian cancer Disease Background and Overview

7. Ovarian cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Ovarian cancer

9. Ovarian cancer Current Treatment and Medical Practices

10. Unmet Needs

11. Ovarian cancer Emerging Therapies

12. Ovarian cancer Market Outlook

13. Country-Wise Ovarian cancer Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Ovarian cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Ovarian cancer Market Outlook 2034 https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Ovarian cancer Pipeline Insights, DelveInsight

"Ovarian cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Ovarian cancer market. A detailed picture of the Ovarian cancer pipeline landscape is provided, which includes the disease overview and Ovarian cancer treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ovarian-cancer-market-epidemiology-treatments-and-key-players-delveinsight-leading-companies-active-in-this-space-include-pharmaand-gmbh-glaxosmithkline-abbvie-eli-lilly-novartis-roche-ve]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.